Radioactive cancer drug enters first human tests
NCT ID NCT06824155
Summary
This is a very early study to test the safety and find the right dose of a new radioactive drug called 177Lu-RAD202 for people with advanced HER2-positive solid tumors. The study will enroll about 30 adults whose cancer has progressed after standard treatments. First, a small 'imaging' dose is given to see where the drug goes in the body, followed by a higher 'treatment' dose to see if it is safe and tolerable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GenesisCare Murdoch
RECRUITINGMurdoch, Western Australia, 6150, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Macquarie University Hospital
RECRUITINGMacquarie Park, New South Wales, 2109, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nepean Hospital
RECRUITINGKingswood, New South Wales, 2747, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St Vincents Hospital, Melbourne
NOT_YET_RECRUITINGFitzroy, Victoria, 3065, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Wollongong Hospital
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.